37122-50-2

Usage

Synthesis Reference(s)

Tetrahedron, 63, p. 2414, 2007 DOI: 10.1016/j.tet.2007.01.014

Upstream product

• 874-60-2 4-methyl-benzoyl chloride 
• 107-15-3 ethylenediamine 
• 131543-46-9 Glyoxal 
• 104-87-0 4-methyl-benzaldehyde 
• 288-32-4 1H-imidazole 
• 106-49-0 p-toluidine 
• 104-85-8 para-methylbenzonitrile 
• 108-88-3 toluene 
• 50846-98-5 2-Diazo-2H-imidazole 
• 13623-58-0 2-(p-tolyl)imidazoline 

Downstream Products

• 61698-35-9 2-p-tolyl-4,5-dihydroxymethyl imidazole 
• 1253697-52-7 1-(phenylsulfonyl)-2-(p-tolyl)-1H-imidazole 
• 1400866-40-1 C₁₉H₁₉N₃O 
• 1400866-42-3 C₁₉H₁₈ClN₃O 

Relevant academic research and scientific papers

A sustainable approach towards the three-component synthesis of unsubstituted 1H-imidazoles in the water at ambient conditions

A green protocol for the synthesis of unsubstituted imidazoles has been demonstrated herein. The reaction is realized using commercially available lipase enzyme, porcine pancreas lipase (PPL) in water. The reaction conditions are selective and mild which helped to tolerate a wide variety of functional groups to give the desired products in good chemical yields. (Figure presented.).

Fe3O4/SiO2/(CH2)3N+Me3Br3- core-shell nanoparticles: A novel catalyst for the solvent-free synthesis of five- and six-membered heterocycles

Functionalized magnetic core-shell nanoparticles [Fe3O4/SiO2/(CH2)3N+Me3Br3-] are prepared by co-precipitation method, characterized by transmission electron microscopy, FT-IR, X-ray diffraction, and vibrating sample magnetometer. The catalytic activity of these nanoparticles was tested in the syntheses of imidazole, benzothiazole, and perimidine derivatives, under solvent-free conditions. The catalyst was readily recycled by the use of an external magnetic field and could be reused five times without significant loss of activity or mass.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Multi-wall carbon nanotube supported manganese(III) porphyrin: An efficient and reusable catalyst for oxidation of 2-imidazolines with sodium periodate

The oxidation of 2-substituted imidazolines with sodium periodate catalyzed by tetrakis(p-aminophenyl)-porphyrinatomanganese(III) chloride, [Mn(TNH 2PP)Cl], supported on functionalized multi-wall carbon nanotubes is reported. A wide variety of 2-imidazolines were efficiently converted to their corresponding imidazoles by this catalytic system. When the same reaction was subjected to ultrasonic irradiation, the reaction times were reduced significantly and the product yields were increased. This catalyst could be reused several times without significant loss of activity. The effects of reaction parameters such catalyst amount, choice of solvent, and the effects of ultrasonic irradiation on the catalytic activity have been investigated.

Synthesis, antimycobacterial activities and Docking studies of some novel diaryl imidazoles targeted at mycobacterium tuberculosis P-45014DM

A novel series of nine 2-(substituted phenyl)-1H-imidazol-1-yl-N- (substituted phenyl) alkanamides 3a-i were synthesized by reacting the corresponding w-chloroalkanamides 1 with 2-(substituted phenyl)-1H-imidazoles 2 in dimethylformamide. The compounds have been characterized on the basis of elemental analysis and spectral data. All the compounds were evaluated for their antimycobacterial activity. Among the synthesized compounds, N-(2,4-dinitrophenyl)-2-(2-(2-nitrophenyl)-1 H-imidazol-2-yl) propanamide 3e showed significant antimycobacterial activity when compared with the standard drug ethambutol. Docking studies with 14-a-demethylase (PDB ID IEA1) were also performed in order to investigate the binding pattern of these compounds.

An efficient and convenient synthesis of imidazolines and benzimidazoles via oxidation of carbon-nitrogen bond in water media

The metal coordination complex K4[Fe(CN)6] is an efficient and environmentally benign catalyst for the synthesis of imidazolines and benzimidazoles from various aldehydes and 1,2-diamines in aqueous medium at room temperature. This protocol gives excellent yield of product with desired purity. Copyright

Rapid and efficient biomimetic oxidation of 2-imidazolines to their corresponding imidazoles with NaIO4 catalyzed by Mn(salophen)Cl

Rapid and efficient oxidation of 2-substituted imidazolines with sodium periodate is reported. The Mn(III)-salophen/NaIO4 catalytic system efficiently converted 2-imidazolines to their corresponding imidazoles at room temperature in 2: 1, CH3CN/H2O mixture.

Oxidation of 2-imidazolines to 2-imidazoles with sodium periodate catalyzed by polystyrene-bound manganese(III) porphyrin

In the present work, the dehydrogenation of 2-substituted imidazolines with sodium periodate in the presence of tetraphenylporphyrinatomanganese(III) chloride supported on polystyrene-bound imidazole, [Mn(TPP)Cl@PSI] is reported. A wide variety of 2-imidazolines were efficiently converted to their corresponding imidazoles by the [Mn(TPP)Cl@PSI]/NaIO4 catalytic system in a 1:2 CH3CN/H2O mixture under agitation with magnetic stirring. Ultrasonic irradiation enhanced the catalytic activity of this catalyst in the oxidation of 2-imidazolines and this led to shorter reaction times and higher product yields. This catalyst could be reused several times without significant loss of its catalytic activity.

Dehydrogenation of 2-imidazolines with sodium periodate catalyzed by manganese(III) tetraphenylporphyrin

In the present work, dehydrogenation of 2-substituted imidazolines with sodium periodate in the presence of tetraphenylporphyrinatomanganese(III) chloride, [Mn(TPP)Cl], is reported. A wide variety of 2-imidazolines efficiently converted to their corresponding imidazoles by [Mn(TPP)Cl]/NaIO4 catalytic system at room temperature in 1:2, CH3CN/H2O mixture. The effect of reaction parameters such as kind of solvent and catalyst amount was also investigated.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.